Disc Medicine Inc (IRON) FinancialsIRONDisc Medicine Inc

Evaluating the bottom line, Disc Medicine, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -39.08%, provide a clear picture of how effectively IRON converts its operational activities into shareholder value.

In the context of the broader market, IRON competes directly with industry leaders such as CLDX and RXRX. With a market capitalization of $2.69B, it holds a leading position in the sector. When comparing efficiency, IRON's gross margin of N/A stands against CLDX's 100.00% and RXRX's -49.82%. Such benchmarking helps identify whether Disc Medicine, Inc. is trading at a premium or discount relative to its financial performance.

Disc Medicine has reported negative net income for several quarters, with Q2 2026 showing a loss of -59,532,000 USD. The company has a forward P/E ratio of 0, indicating no earnings expected in the near term, and a price-to-book ratio of 3.69884, suggesting it may be overvalued relative to its book value.